Supplementary Table 4. Study characteristics of included studies for each of the meta-analysis outcomes.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Studies with sepsis/severe sepsis/septic shock outcome**  **n=16** | **Patients included in sepsis/severe sepsis/septic shock outcome**  **N=9,629** | **Studies with mortality outcome**  **n=69** | **Patients included in mortality outcome**  **n=145,461** |
|  | n (%) | n (%) | n (%) | n (%) |
| Publication year |  |  |  |  |
| 2004 - 2008 | 1 (6.3) | 151 (1.5) | 7 (10.1) | 7,710 (5.3) |
| 2009 - 2012 | 0 (0) | 0 (0) | 5 (7.2) | 1,499 (1.0) |
| 2013 - 2016 | 3 (18.7) | 1,635 (17.0) | 11 (16.0) | 52,169 (35.9) |
| 2017 - 2020 | 12 (75.0) | 7,843 (81.5) | 46 (66.7) | 84, 083 (57.8) |
| Participating sites |  |  |  |  |
| 1 | 12 (75.0) | 7,591 (78.8) | 49 (71.0) | 10,717 (7.4) |
| 2 - 5 | 1 (6.3) | 1,121 (11.6) | 2 (2.9) | 160 (0.1) |
| 6 - 10 | 2 (12.5) | 454 (4.7) | 4 (5.8) | 1,581 (1.1) |
| > 10 | 1 (6.3) | 464 (4.8) | 14 (20.3) | 133,003 (91.4) |
| Region of primary sitea |  |  |  |  |
| North America | 1 (6.3) | 6,303 (65.5) | 14 (20.3) | 129,999 (89.0) |
| Latin America and Caribbean | 3 (18.8) | 735 (7.6) | 10 (14.5) | 3,006 (2.1) |
| Europe and Central Asia | 2 (12.5) | 252 (2.6) | 11 (15.9) | 3,555 (2.4) |
| East Asia and Pacific | 4 (25.0) | 631 (6.6) | 16 (23.2) | 7,504 (5.2) |
| South Asia | 3 (18.8) | 338 (3.5) | 13 (18.8) | 1,535 (1.1) |
| Middle East and North Africa | 1 (6.3) | 189 (2.0) | 4 (5.8) | 352 (0.2) |
| Central and South America | 0 (0) | 0 (0) | 1 (1.4) | 110 (0.1) |
| Sub-Saharan Africa | 2 (12.5) | 0 (0) | 0 (0) | 0 (0) |
| World Bank Income Classification | | | |  |
| High Income Country | 5 (31.3) | 7,047 (73.2) | 28 (40.6) | 134,899 (92.7) |
| Upper Middle-Income Country | 6 (37.5) | 1,063 (11.0) | 25 (36.2) | 8,860 (6.1) |
| Lower Middle-Income Country | 4 (25.0) | 398 (4.1) | 16 (23.2) | 1,702 (1.2) |
| Lower Income Country | 1 (6.3) | 1,121 (11.7) | 0 (0) | 0 (0) |
| Study design |  |  |  |  |
| Randomized controlled trialb | 0 (0) | 0 (0) | 1 (1.4) | 50 (0) |
| Prospective cohort | 8 (50.0) | 2,430 (25.2) | 31 (44.9) | 7,732 (5.3) |
| Retrospective cohort | 5 (31.3) | 7,001 (72.7) | 34 (49.3) | 137,290 (94.4) |
| Case-control | 3 (18.8) | 198 (2.1) | 3 (4.3) | 389 (0.3) |
| Primary study settingc |  |  |  |  |
| Pediatric Intensive Care Unit | 11 (68.8) | 8,042 (83.5) | 61 (88.4) | 143,016 (98.3) |
| Emergency Department | 2 (12.5) | 180 (1.9) | 6 (8.7) | 1,898 (1.3) |
| Ward | 3 (31.3) | 1,472 (15.3) | 6 (8.7) | 25,394 (17.5) |
| Other | 0 (0) | 0 (0) | 0 (0) | 0 (0) |

aSite of the corresponding author and or location of research ethics approval using the World Bank Classification of 2019-2020.

bSecondary analysis of a randomized controlled trial

cSeveral studies included more than one primary site resulting in a total of greater than 69 sites and 100%.